Please login to the form below

Not currently logged in
Email:
Password:

PRV

This page shows the latest PRV news and features for those working in and with pharma, biotech and healthcare.

FDA follows EMA with approval of Merck’s Ebola vaccine

FDA follows EMA with approval of Merck’s Ebola vaccine

Merck can either use the PRV to fast-track an FDA review of one of its own products, or sell it on to another company.

Latest news

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 145. Sarepta Therapeutics/  Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy. ... Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv

  • Pharma deals in August 2015 Pharma deals in August 2015

    In 2012 the PRV programme was extended to include rare pediatric diseases and the emergence of trading in PRVs was noted in our last annual Deal Watch report. ... Keeping this trend, United Therapeutics has sold a PRV to AbbVie for a headline value of

  • Pharma deals in May 2015 Pharma deals in May 2015

    The paediatric PRV was issued when Cholbam was approved for the treatment of patients with peroxismal disorders. ... 300. Retrophin/ Sanofi. Acquisition of priority review voucher [PRV]. For Cholbam [cholic acid] in bile acid disorders.

  • Pharma deals during November 2014 Pharma deals during November 2014

    BioMarin was awarded a Rare Pediatric Disease PRV when it received approval of Vimizim, a new biological product for patients with Mucopolysaccharidosis type IVA. ... Selling PRVs is a relatively new area and so these two deals provide initial benchmarks,

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...

Infographics